What is AFUNDAS-L 70mg
AFUNDAS-L 70mg is an antifungal medication containing the active ingredient Caspofungin, presented as a powder for concentrate for solution for infusion. It belongs to a class of antifungals known as echinocandins. This medicine is used to treat serious fungal infections, particularly in hospitalized or immunocompromised patients.
- Active Ingredient: Caspofungin acetate
- Form: Powder for concentrate for solution for infusion
- Strength: 70 mg per glass vial
- Common Use: Treatment of invasive candidiasis, esophageal candidiasis, and invasive aspergillosis (especially in cases resistant or intolerant to other antifungals like amphotericin B or itraconazole)
This medication is often reserved for patients who are severely ill, such as those in intensive care, oncology, or hematology units, where systemic fungal infections pose a life-threatening risk.
How to use AFUNDAS-L 70mg
AFUNDAS-L should be administered in a hospital setting under the supervision of experienced healthcare professionals. The powder is reconstituted and diluted before intravenous infusion.
- Preparation: The contents of the vial are first reconstituted with sterile water for injection, then further diluted in a compatible intravenous fluid like 0.9% Sodium Chloride or 5% Dextrose.
- Administration: Administered by slow intravenous infusion over approximately 1 hour, once daily.
- Initial Dose: Usually a loading dose of 70 mg on Day 1.
- Maintenance Dose: 50 mg daily from Day 2 onward (adjusted depending on the clinical condition).
Important Considerations:
- Do not administer as a rapid IV injection or bolus.
- Inspect solution visually for particulate matter before use.
- Dosing must be adjusted in hepatic impairment or if drug interactions are likely.
- Ensure compatibility with other IV drugs; use a separate IV line if needed.
Mode of Action AFUNDAS-L 70mg
AFUNDAS-L works by targeting the fungal cell wall, which is essential for fungal survival and growth. Specifically, Caspofungin acts on the synthesis of a key polysaccharide called 1,3-β-D-glucan.
- Mechanism: Inhibits the enzyme β-(1,3)-D-glucan synthase, which is responsible for forming 1,3-β-D-glucan in fungal cell walls.
- Result: Weakens the cell wall, causing osmotic instability and leading to cell lysis and death.
- Target: Most Candida species and Aspergillus species.
Advantages of Echinocandins like Caspofungin:
- Fungicidal activity against Candida spp.
- Fungistatic activity against Aspergillus spp.
- Low toxicity to human cells, as human cells lack a cell wall
- Low potential for cross-resistance with other antifungal classes like azoles or polyenes
AFUNDAS-L 70mg Interactions AFUNDAS-L 70mg
Like many antifungals, AFUNDAS-L (Caspofungin) can interact with other medications that affect liver enzyme activity, especially cytochrome P450 inducers and inhibitors.
- Cyclosporine: May increase Caspofungin levels and liver enzyme elevations; monitor liver function tests.
- Rifampin, Phenytoin, Carbamazepine: These enzyme inducers may decrease Caspofungin levels, requiring dose adjustment to maintain efficacy.
- Dexamethasone: Can also lower Caspofungin levels via hepatic enzyme induction.
- Tacrolimus: Caspofungin may slightly increase tacrolimus levels; monitor drug levels if co-administered.
General Guidelines:
- Always review the patient’s full medication list before starting AFUNDAS-L.
- Monitor liver enzymes regularly during co-administration with hepatically metabolized drugs.
- Use caution in transplant patients or those on multiple immunosuppressants.
Dosage of AFUNDAS-L 70mg
Dosage of AFUNDAS-L depends on the type of fungal infection, patient weight, liver function, and presence of other medications.
- Loading Dose: 70 mg IV on Day 1 (infused over ~1 hour)
- Maintenance Dose: 50 mg IV once daily from Day 2 onwards
- For Invasive Candidiasis: Continue for at least 14 days after the last positive culture and resolution of symptoms
Adjustments:
- Hepatic impairment (moderate): Reduce maintenance dose to 35 mg daily
- Renal impairment: No dose adjustment needed
- Pediatric Use: Doses are calculated based on body surface area
- Elderly: No routine dosage adjustment needed unless hepatic function is impaired
Always follow physician or institutional guidelines and individualize therapy based on patient response and microbiological results.
Possible side effects of AFUNDAS-L 70mg
Most patients tolerate AFUNDAS-L well, but as with all medications, side effects may occur. These can range from mild infusion-related reactions to more serious systemic effects.
- Common Side Effects:
- Fever
- Headache
- Infusion-related reactions (rash, itching, facial swelling)
- Elevated liver enzymes (AST, ALT, ALP)
- Gastrointestinal discomfort (nausea, vomiting, diarrhea)
- Less Common:
- Phlebitis at injection site
- Back pain
- Hypokalemia
- Anemia
- Serious (Rare):
- Anaphylaxis or severe hypersensitivity
- Hepatotoxicity
- Cardiac arrhythmias
Patients should be closely monitored during treatment, particularly during the first infusion. Any unusual symptoms should be reported to the healthcare provider immediately.
AFUNDAS-L 70mg Contraindications AFUNDAS-L 70mg
Although AFUNDAS-L is considered safe in most hospitalized patients, certain contraindications and cautionary scenarios must be considered.
- Known Hypersensitivity: Contraindicated in patients with a history of allergy to Caspofungin or any echinocandin component.
- Severe Hepatic Impairment: Use with caution and under close monitoring; may require dose adjustment.
- Pregnancy and Lactation: Not well studied in pregnant or breastfeeding women. Use only if clearly necessary and prescribed by a specialist.
- Pediatric Use: Should be used with adjusted doses under specialist supervision.
Use with caution in:
- Patients with multiple co-administered drugs that are hepatically metabolized
- Immunosuppressed individuals, where infection masking may delay diagnosis of side effects
- Patients undergoing chemotherapy or with hematologic malignancies
Storage of AFUNDAS-L 70mg
Proper storage of AFUNDAS-L is crucial to maintaining its stability and therapeutic efficacy.
- Storage Conditions (Unreconstituted): Store the vials at 2°C to 8°C (refrigerated), protected from light.
- After Reconstitution: The concentrate can be stored at room temperature (up to 25°C) for a limited time—usually not more than 24 hours prior to dilution.
- After Dilution: The final infusion solution should be used within 24 hours if stored at room temperature or 48 hours if refrigerated.
Additional Notes:
- Do not freeze the reconstituted or diluted solution.
- Visually inspect for particles or discoloration before use.
- Use aseptic technique during preparation to avoid contamination.
- Keep out of reach of children and do not use past expiry date.
AFUNDAS-L 70mg features an exceptional active ingredient renowned for its potent effects, comprising Caspofungin. This powerful formulation provides a superior solution for addressing diverse health concerns. With 70mg/Vial concentration and an easily manageable Infusion/Powder for concentrate for solution for, it remains a preferred option for countless individuals seeking effective treatment.
Introduction
All you need to know about AFUNDAS-L 70mg .
Welcome to Dwaey, specifically on AFUNDAS-L 70mg page.
This medicine contains an important and useful components, as it consists of Caspofungin.
AFUNDAS-L 70mg is available in the market in concentration 70mg/Vial and in the form of Infusion/Powder for concentrate for solution for.
GENSENTA ?LA‚ SANAY? VE T?CARET A.?. is the producer of AFUNDAS-L 70mg and it is imported from TURKEY,
The most popular alternatives of AFUNDAS-L 70mg are listed downward .
-
Active Substance
-
Size
-
Indications
- No indications available.
-
Type
Infusion/Powder for concentrate for solution for
-
Company
GENSENTA ?LA‚ SANAY? VE T?CARET A.?.
Frequently Asked Questions
AFUNDAS-L 70mg should be stored according to the instructions provided by GENSENTA ?LA‚ SANAY? VE T?CARET A.?..
In general, it is recommended to store AFUNDAS-L 70mg in a cool, dry place, away from direct sunlight
and out of the reach of children.
The duration of treatment with AFUNDAS-L 70mg may vary depending on the condition being treated
and the guidance of your healthcare provider. It is important to follow the prescribed treatment
plan and continue taking AFUNDAS-L 70mg for the recommended duration, even if your symptoms improve.
If you have any concerns or questions about the duration of treatment, consult your healthcare provider.
It is important to check with your healthcare provider or read the medication label for specific
instructions regarding alcohol consumption while taking AFUNDAS-L 70mg. Some medications, including
AFUNDAS-L 70mg, may have interactions with alcohol that can reduce effectiveness, increase side
effects, or pose other risks to your health. It is best to follow the guidance provided by your
healthcare professional.
If you miss a dose of AFUNDAS-L 70mg, take it as soon as you remember. However, if it is close
to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing
schedule. Do not take a double dose to make up for a missed one unless advised by your healthcare provider.
No, do not stop taking AFUNDAS-L 70mg without consulting your healthcare provider, even if your
symptoms improve. It is important to complete the full course of treatment as prescribed. Stopping
the medication prematurely may lead to a relapse or incomplete resolution of the condition. If you
have concerns about the duration of treatment, consult your healthcare provider for guidance.
It is important to consult your healthcare provider before taking AFUNDAS-L 70mg if you are
pregnant or breastfeeding. They will be able to assess the potential risks and benefits based on your
specific situation. Please note that the safety and suitability of AFUNDAS-L 70mg during pregnancy
or breastfeeding may depend on the active substance [Active Substance], concentration 70mg/Vial,
and the specific recommendations of GENSENTA ?LA‚ SANAY? VE T?CARET A.?..
The effects of AFUNDAS-L 70mg on your ability to drive or operate machinery can vary depending on
the active substance [Active Substance], concentration 70mg/Vial, and individual factors.
Some medications may cause drowsiness, dizziness, or other side effects that can impair your judgment
or coordination. It is important to read the medication label or consult your healthcare provider to
understand any potential effects on your ability to perform tasks that require alertness.
The instructions for taking AFUNDAS-L 70mg with or without food may vary depending on the medication
and the recommendations of GENSENTA ?LA‚ SANAY? VE T?CARET A.?.. Some medications may be more effective when taken with
food to enhance absorption or reduce stomach irritation, while others may need to be taken on an empty
stomach for optimal absorption. Read the medication label or consult your healthcare provider for specific instructions.
The use of AFUNDAS-L 70mg in children or elderly individuals may depend on various factors, including
the specific medication, type Infusion/Powder for concentrate for solution for, and the recommendations of GENSENTA ?LA‚ SANAY? VE T?CARET A.?.. Some
medications may have specific dosing instructions or precautions for these age groups. Consult your
healthcare provider or read the medication label for information regarding the safe and appropriate use
of AFUNDAS-L 70mg in children or elderly individuals.
Dwaey
All medical information published on the Dwaey website aims to increase medical awareness and health education among users. However, it is not a substitute for professional medical advice. Always consult with a specialist doctor. We strongly advise against using any information or medicine found on the site without referring to your healthcare provider.
Related Products
0 Comments